


**REMARKS**

Claims 1-12 are pending in this application. The Examiner has required restriction to one of two (2) groups. In response to such restriction, Applicants wish to proceed as follows.

Applicants elect with traverse Group II (claims 4-6, 8, 10, 12), drawn to a method of reducing or preventing development of liver fibrosis comprising administering to a mammalian subject in need of such treatment a therapeutically effective amount of an FXR agonist, and select the species of claim 6 (Formula II), for prosecution on the merits. Claims 1-3, 7, 9 and 11 are hereby withdrawn. After entry of the present amendment, claims 4-6, 8, 10 and 12 will be pending. Applicants expressly reserve the right to pursue the subject matter of the non-elected claims that have been assigned to group I in one or more divisional application(s).

Applicants believe the present claims are in condition for allowance and such action is respectfully requested. If the Examiner has any outstanding issues with the pending claims, he is encouraged to telephone the undersigned at (919) 483-8406 for expeditious handling.

Respectfully submitted,



Robert (Steve) Thomas  
Attorney for Applicants  
Registration No. 52,284

Date: 2/26/2009  
Customer No. 23347  
GlaxoSmithKline  
Corporate Intellectual Property  
Five Moore Drive, P.O. Box 13398  
Research Triangle Park, NC 27709-3398  
Telephone: (919) 483-8406  
Facsimile: (919) 483-7988